Welcome to our dedicated page for Enovix Corporation SEC filings (Ticker: ENVXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ENVXW SEC filings page focuses on regulatory documents related to the Enovix Corporation warrants that traded under the ENVXW symbol. These filings help explain how the warrant program was structured, how it evolved over time, and how the ENVXW class was ultimately removed from listing on the Nasdaq Stock Market.
Key filings include multiple Form 8-K reports in which Enovix describes material events affecting the warrants. These 8-Ks summarize press releases announcing the distribution of the warrants as a dividend, the satisfaction of early expiration price conditions tied to the volume-weighted average price of Enovix common stock, the election of an alternate expiration date, and the mechanics by which warrants had to be exercised before they became void. The filings also reference a Notice of Guaranteed Delivery that outlined procedures for warrant holders whose financial institutions could not complete exercises before the deadline.
A central document for ENVXW is the Form 25 filed with the SEC, in which Nasdaq notified the Commission of the removal of the Enovix warrant class from listing and registration under Section 12(b) of the Exchange Act. This filing confirms that the ENVXW warrants, described simply as “Warrant” in the form, were struck from the exchange following the conclusion of the program.
Through Stock Titan, users can access these filings as they appear on EDGAR, while AI-powered tools can assist in interpreting the implications. For ENVXW, that means quickly understanding the timeline from warrant issuance to expiration, the conditions that triggered early expiration, and the formal delisting process. Users interested in Enovix more broadly can also look to related filings under ENVX for annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks that discuss financial results, capital markets transactions and governance changes.
In addition, investors researching historical capital structure or derivative securities can use the ENVXW filings to see how the warrant terms were documented in the warrant agreement, how the company communicated with holders, and how proceeds from exercises were reported in subsequent disclosures. AI summaries can highlight the sections that address warrant exercise prices, expiration conditions, and the impact on Enovix’s equity.
Enovix Corporation reported that a pricing condition for its publicly traded warrants (trading under ENVXW) has been met and that it has chosen Friday, August 29, 2025 as an alternate expiration date for these warrants. Trading in the warrants on Nasdaq will end at 4:00 p.m. New York City time on that date, and holders must exercise their warrants by 5:00 p.m. New York City time the same day. After that time, the warrants will no longer be exercisable, will be void, and any holders who have not exercised will lose all rights associated with those warrants.
Enovix Corporation announced that the volume-weighted average price (VWAP) of its common stock exceeded $10.50 for the required number of trading days, triggering the early expiration condition for its Nasdaq-listed ENVXW warrants under a July 21, 2025 Warrant Agreement. The company elected to set August 29, 2025 as the alternate expiration date for these warrants.
The ENVXW warrants are scheduled to stop trading on Nasdaq at 4:00 p.m. New York City time on August 29, 2025, and holders must exercise them by 5:00 p.m. that day, in each case so long as the VWAP of the common stock is at least $8.75 for each of the two trading days immediately before the expiration date. After 5:00 p.m. on August 29, 2025, any unexercised warrants will be void and their holders will have no further rights. A press release and a Notice of Guaranteed Delivery for warrant exercise are filed as exhibits.
Enovix Corp. director John Daniel McCranie received grants of restricted stock units (RSUs) totaling 40,878 shares on 08/12/2025, recorded on a Form 4 filed 08/26/2025. The filing shows two non‑derivative entries: 25,700 RSUs that will vest in 12 equal quarterly installments beginning August 12, 2025, and 15,178 RSUs with 25% vesting on November 12, 2025, February 12, 2026, May 12, 2026 and the earlier of June 12, 2026 or the company’s 2026 annual meeting (or immediately prior if the director does not stand for or is not re‑elected), subject to continued service.
The transactions are recorded at a $0 price per share, reflecting compensation grants rather than open‑market purchases, and the Form 4 was submitted by an attorney‑in‑fact for the reporting person.
Enovix Corp director reports no share ownership
Enovix Corp director J. Daniel McCranie filed an initial Form 3 stating that he beneficially owns no securities of the company. The filing, made as a single reporting person, confirms there are no non-derivative or derivative holdings to disclose.
Enovix Corp reporting person Ryan A. Benton, the company’s Chief Financial Officer and a director, received a fully vested award of 5,132 restricted stock units that settled into common stock on 08/22/2025. The filing shows 2,895 shares were withheld to satisfy tax obligations related to that RSU settlement. The report lists the reporting person’s beneficial ownership after the transactions as 753,884 shares in one line and 750,989 shares in another, with explanatory notes indicating the holdings include shares issuable upon settlement of outstanding RSUs.
Enovix Corp (ENVX) Chief Legal Officer Arthi Chakravarthy reported stock activity tied to vested restricted stock units. On 08/22/2025 Ms. Chakravarthy received 5,251 shares upon the settlement of fully vested RSUs that represent her bonus for the quarter ended 06/29/2025. To satisfy tax withholding she permitted the withholding/ disposition of 2,776 shares on 08/22/2025 and an additional 2,217 shares on 08/24/2025, each at a reported price of $10.51. Following these transactions the filing reports beneficial ownership totals of 433,434, then 430,658, and then 428,441 shares, with disclosed shares issuable upon RSU settlement of 343,244, 337,993, and 333,800 respectively. The form is signed 08/26/2025.
Enovix Corp (ENVX) insider Ajay Marathe reported equity transactions on Form 4 dated 08/22/2025. Marathe, who serves as Chief Operating Officer, received 7,449 shares of common stock upon settlement of fully vested restricted stock units (RSUs) that represent a quarterly bonus for the period ended June 29, 2025. To satisfy tax withholding on that issuance, 3,937 shares were withheld and disposed of at a price of $10.51 per share. After these transactions Marathe beneficially owned 1,160,527 shares (the filing also notes 1,164,464 and 1,160,527 as post-transaction tallies reflecting RSU totals). The form was signed by an attorney-in-fact on 08/26/2025.
Enovix Corp (ENVX): Raj Talluri, the company's President, CEO and a director, received a fully vested award of restricted stock units (RSUs) on 08/22/2025 as a quarterly bonus. The grant resulted in the issuance of 14,866 shares of common stock at no cash cost to the reporting person and increased his total reported beneficial ownership to 2,398,067 shares, which includes 1,868,718 shares issuable upon settlement of RSUs.
The filing also shows the withholding of 7,857 shares to satisfy tax obligations related to the RSU settlement; those shares were treated as disposed at an effective price of $10.51, leaving 2,390,210 shares reported after withholding, including 1,853,852 shares issuable upon settlement of RSUs. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Raj Talluri, Enovix Corporation's President and CEO and a director, reported transactions in the company's common stock and publicly traded warrants. On 08/18/2025, 17,617 shares of common stock were disposed of at $10.17 per share to satisfy tax withholding related to RSUs that vested that day. Following the transaction, the reporting person beneficially owned 2,383,201 shares, which includes 1,853,852 shares issuable upon settlement of outstanding RSUs. Separately, on 08/15/2025 the reporting person sold 30,187 warrants for a weighted-average price of $1.6814 per warrant; the warrants, distributed on 07/21/2025 at no cost, have an $8.75 exercise price and expire on 10/01/2026 unless accelerated. The Form 4 was signed by an attorney-in-fact on 08/22/2025.
Enovix Corp director Joseph Ian Malchow reported sales of publicly traded warrants issued July 21, 2025. The Form 4 shows warrants (exercise price $8.75) that were distributed to the reporting person at no cost were sold in the public market on 08/15/2025 at prevailing market prices. The filing lists three warrant lots sold: 58,437; 628; and 185 warrants, each exercisable into one share of common stock and expiring on 10/01/2026 (subject to early acceleration conditions). Holdings following the transactions are reported as 0 shares for the sold warrants; some underlying shares were held jointly with spouse and by a minor child.